CYCLONE 3: what clinicians are saying
abemaciclib plus abiraterone in high-risk metastatic hormone-sensitive prostate cancer · NCT05288166 ↗ · Phase 3 · Eli Lilly and Company
For CYCLONE 3, a medical oncologist considered benefit less likely after reporting a CYCLONE-2 setback in castration-resistant disease, but left the answer to trials then underway. Gastrointestinal effects and low blood counts were raised in one discussion without a risk–benefit verdict. The cited commentary does not address the posted results, leaving clinicians’ interpretation of those results unknown.
Created with AI · how we check it
- edition 1
- commentary checked Nov 17, 2026
- 218 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
11 findings, and what sits behind each
01. CDK4/6–AR rationale: why speakers see prostate cancer benefit as an open question
1 of the report's 11 cited clinicians · 12 statements from 2 speakers in 8 sources, 5 of them podcasts or videos · 15 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison.
02. CDK4/6 in prostate cancer: what speakers say
No named clinician · accounts and unnamed speakers · 2 statements in 2 sources, 1 of them a podcast or video · 2 passages
Limitations recorded: 2.
Draws on: Safety and tolerability.
03. CYCLONE 3: what speakers say
1 of the report's 11 cited clinicians · 10 statements from 3 speakers in 6 sources, 3 of them podcasts or videos · 13 passages
Limitations recorded: 3.
Draws on: Design and conduct, Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator, Population and setting, The comparison, Secondary endpoints.
Beyond the trial population
04. Triplets: what speakers say
3 of the report's 11 cited clinicians · 18 statements from 3 speakers in 3 sources, all podcasts or videos · 15 passages
Limitations recorded: 4.
05. This lung-only relapse: what speakers say
No named clinician · accounts and unnamed speakers · 11 statements in 2 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
06. MHSPC: most clinicians usually escalate when apt—one rarely holds ADT for harm
3 of the report's 11 cited clinicians · 11 statements from 3 speakers in 3 sources, all podcasts or videos · 10 passages
Limitations recorded: 4.
07. Hormonal partners: how clinicians weigh tolerability, comorbidity and cost
2 of the report's 11 cited clinicians · 19 statements from 2 speakers in 4 sources, all podcasts or videos · 9 passages
Limitations recorded: 4.
08. Chemo-free darolutamide: a clinician seeks selective access—one awaits data
2 of the report's 11 cited clinicians · 7 statements from 2 speakers in 3 sources, all podcasts or videos · 4 passages
Limitations recorded: 3.
09. Genetic work-up: what speakers say
4 of the report's 11 cited clinicians · 23 statements from 5 speakers in 8 sources, 4 of them podcasts or videos · 19 passages
Limitations recorded: 3.
10. PEACE-1 prostate RT: what speakers say
3 of the report's 11 cited clinicians · 15 statements from 3 speakers in 4 sources, 3 of them podcasts or videos · 11 passages
Limitations recorded: 4.
11. Hard de novo doublet/triplet cases: a clinician weighs chance in a neuroendocrine rise
2 of the report's 11 cited clinicians · 13 statements from 2 speakers in 3 sources, all podcasts or videos · 11 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 11
1 of the report's 11 cited clinicians
CDK4/6–AR rationale: why speakers see prostate cancer benefit as an open question
12 statements from 2 speakers in 8 sources, 5 of them podcasts or videos
2 of the 2 named speakers in this finding hold this view
- 12
- statements
- 15
- passages
- 8
- sources
- 2
- speakers
What the statements areViews 8Questions and uncertainty 3Clinical experience 0Comparisons 0Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 12Giving context 8Recorded with the findingLimitations: 3
2 posts and articles · 5 podcasts and video · 1 registry
Draws on: Population and setting, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
8 of the 11 findings and 114 of the 218 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (6)
ADT, androgen deprivation therapy; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; PSMA, prostate-specific membrane antigen; RT, radiotherapy.
The full CYCLONE 3 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians still need to see in CYCLONE 3 to establish whether adding abemaciclib to abiraterone translates the CDK4/6–androgen receptor rationale into clinical benefit in high-risk metastatic hormone-sensitive prostate cancer?
From finding F1 (12 statements from 2 speakers in 8 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 41commentary sources screened
- 15sources cited by verified statements
- 14named in screened sources
- 14speakers cited in the report
- 13cited speakers with a verified identity
11 cited clinicians, speakers with a confirmed clinical role, of them 11 physicians. By role and specialty:
- 6 physician, Medical oncology
- 3 physician, specialty not confirmed
- 1 physician, Surgical oncology
- 1 physician, Urology
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 218verified statements, each linked to its source
- 54of them from speakers with a confirmed clinical role
- 11findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 218 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 13 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 15 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
14 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator | 3 | 3 |
| Secondary endpoints | 2 | 2 |
| Population and setting | 8 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 7 | 5 |
| Safety and tolerability | 8 | 2 |
| Design and conduct | 7 | 4 |
| Biological rationale and uncertainty about clinical translation | 18 | 7 |
| Doublet versus chemotherapy-containing triplet selection | 29 | 4 |
| Disease-site heterogeneity, imaging and diagnostic certainty | 12 | 2 |
| Hormonal-partner choice, cardiovascular coordination and access | 26 | 4 |
| Genetic work-up, prognostic information and patient support | 23 | 8 |
| Prostate-directed radiation, urinary morbidity and referral timing | 14 | 3 |
| Downstream treatment applicability and aggressive progression | 13 | 3 |
| Implementation, uncommon monotherapy exceptions and cautious ADT interruption | 19 | 4 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
218 verified statements from 15 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 198 statements · 91% | ||||
| YouTube | 11 | 1 | 1 | |
| Podcasts | 187 | 4 | 4 | |
| Posts · 12 statements · 5% | ||||
| X threads | 12 | 9 | 36 | |
| Primary sources · 8 statements · 4%cited for context, not screened | ||||
| Registry | 8 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- Sep 10, 2022 → Jan 14, 2025
- Cited window
- Oct 21, 2022 → Sep 16, 2024
- Retrieved
- Nov 15, 2026
The trial
from ClinicalTrials.gov- Title
- CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
- Registry
- NCT05288166
- Study IDs
- 18448 · I3Y-MC-JPEG (Eli Lilly and Company) · 2022-500461-28-06 (EU Trial Number)
- Sponsor
- Eli Lilly and Company
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 925 actual
- Registered
- 2022-03-21
- Start
- 2022-04-14 actual
- Primary completion
- 2024-02-15 actual
- Primary endpoint
- Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
- Interventions
- 4 registered
More on: Prostate cancer, abemaciclib
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on occupational cognitive demands as a reason to consider alternatives to first-line enzalutamide; a remark on abemaciclib’s mechanism and investigational status in metastatic hormone-sensitive prostate cancer; a view on metastasis-directed treatment, systemic therapy deferral, and uncertainty about safely stopping systemic treatment; a view on selecting patients for triplet therapy rather than standard doublet treatment in metastatic hormone-sensitive prostate cancer; a remark on selected-patient triplet evidence and continuing therapeutic need in high-risk metastatic hormone-sensitive prostate cancer; a question about de novo metastatic representation in evidence informing treatment intensification; a view on PSMA-targeted radioligand therapy as an emerging systemic option in metastatic hormone-sensitive prostate cancer; a view on cautious treatment interruption in hormone-sensitive disease because of comorbidities or severe side effects.
- 1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 126 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 13 known gaps +Fewer −
- Further source limits: 30 sources about other trials or topics are not included.
- ClinicalTrials.gov first posted results for CYCLONE 3 on 27 June 2025. The cited commentary dates from October 2022 to September 2024 and predates those results; none of it discusses them. No separate results publication was identified in the sources reviewed for this edition. Protocol objectives and endpoints, and expectations expressed before that posting, must not be read as observed benefit or harm.
- The public discussion located through trial names and identifiers may miss relevant unnamed discussion or differently transcribed references. The report does not represent all HCPs or all public discussion.
- Individual ownership is uncertain for many podcast and video passages. Participation lists, program descriptions and familiar speaker labels do not establish who said those words.
- Several episodes may include overlapping participants, and reposts or quoted posts do not establish additional independent HCP opinions.
- Treatment preferences, approval statements, reimbursement experiences and guideline interpretations are historical as expressed in the sources, rather than current clinical or regulatory guidance.
- Protocol and commentary descriptions differ on some eligibility and design details. Spoken thresholds and prior-docetaxel descriptions are preserved as statements, not silently substituted for the protocol.
- Broader mHSPC practice discussions often include populations, alternatives or later treatment consequences not directly tested by CYCLONE 3; they do not establish abemaciclib benefit in a subgroup.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (tags)
None of these changed a statement, finding or source.
- Nov 17, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 17, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. CYCLONE 3 (NCT05288166): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 17, 2026. https://www.erudio.com/reports/cyclone-3-nct05288166
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "CYCLONE 3" (NCT05288166), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "cyclone-3-nct05288166". If you cannot make requests, read https://www.erudio.com/reports/cyclone-3-nct05288166.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05288166", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05288166 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/cyclone-3-nct05288166.json
curl https://www.erudio.com/reports/cyclone-3-nct05288166.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "cyclone-3-nct05288166" })release 92ea8f640bfc4e3e319463c5000c1c8774c959c9b72f58e5461219d903f8ac0b
Questions
How much does the CYCLONE 3 report cost?
One edition costs $1,250 (Standard · 218 verified statements · 54 from 11 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the CYCLONE 3 report cover?
218 statements from 15 sources (4 podcasts, 1 video, 9 posts, 1 registry record), 54 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 17, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the CYCLONE 3 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "cyclone-3-nct05288166" }) previews it and create_order({ "report": "cyclone-3-nct05288166", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the CYCLONE 3 report?
Edition 1 (version 1.0.0), accepted Nov 17, 2026 UTC; last checked for new commentary Nov 17, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.